Clinical trial NCT02959437: Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)
Official title: A Phase 1/2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Stage IV Microsatellite-Stable Colorectal Cancer (ECHO-206)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
PHASE2
Conditions: Solid Tumors
Advanced Malignancies
Metastatic Cancer
Keywords: Solid tumors
NSCLC
CRC
Lead sponsor: Incyte Corporation
Sponsor class: INDUSTRY
First posted: 2016-11-09
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is an open-label, Phase 1/2 study in subjects with advanced or metastatic solid tumors. The study has three separate treatment groups where separate epigenetic agents are evaluated with an immunotherapy combination. Treatment Group A will evaluate the DNA methyltransferase inhibitor azacitidine in combination with the programmed death receptor-1 (PD-1) inhibitor pembrolizumab and the indoleamine 2,3-dioxygenase (IDO-1) inhibitor epacadostat; Treatment Group B will evaluate the bromodomain and extra-terminal (BET) inhibitor INCB057643 with pembrolizumab and epacadostat; and Treatment Group C will evaluate the lysine-specific demethylase 1A (LSD1) inhibitor INCB059872 with pembrolizumab and epacadostat. The study will be divided into 2 parts (Part 1 and 2). Part 1 is a dose-escalation assessment to evaluate the safety and tolerability of the combination therapies. Once the recommended doses have been determined, subjects with previously treated NSCLC, microsatellite-stable colorectal cancer (CRC), head and neck squamous cell carcinoma, urothelial carcinoma, and melanoma will be enrolled into expansion cohorts in Part 2.


Eligibility criteria: Inclusion Criteria:

* Willingness to provide written informed consent for the study.
* Willingness to undergo a pretreatment and on-treatment tumor biopsy to obtain tumor tissue.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
* Part 1: Subjects with histologically or cytologically confirmed advanced or metastatic solid tumors that have failed prior standard therapy (disease progression; subject refusal or intolerance is also allowable).
* Part 2:

  \*Note: Subjects must have failed available therapies that are known to confer clinical benefit as indicated below, unless they are ineligible, intolerant, or refused standard treatment.
* Subjects with histologically or cytologically confirmed NSCLC:

  * Metastatic (Stage IV) or recurrent NSCLC (according to American Joint Committee on Cancer 7th edition guidelines) who have had disease progression after available therapies for advanced or metastatic disease that are known to confer clinical benefit, been intolerant to treatment, or refused standard treatment.
  * Prior systemic regimens must include previously approved therapies, including a platinum-containing chemotherapy regimen; a tyrosine kinase inhibitor for tumors with driver mutations; and checkpoint inhibitors where approved.
  * Must have disease progression on a prior PD-1-pathway targeted agent.
* Subjects with recurrent (unresectable) or metastatic CRC:

  * Have histologically confirmed microsatellite stable (MSS) CRC.
  * Stage IV MSS CRC (according to American Joint Committee on Cancer 7th edition guidelines) who have had disease progression after available therapies for advanced or metastatic disease that are known to confer clinical benefit, been intolerant to treatment, or refused standard treatment.
  * Prior systemic regimens must include previously approved therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy; an anti-VEGF therapy (if no contraindication); and if negative for KRAS, NRAS, and BRAF mutations and no contraindication, an anti-epidermal growth factor receptor (EGFR) therapy; and progressed after the last administration of approved therapy.
* Subjects with HNSCC:

  * Histologically confirmed squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx.
  * Carcinomas of the nasopharynx, salivary gland, or nonsquamous cell histology are excluded.
  * Must have received prior treatment with a platinum-based therapy
  * Must have had documented disease progression while on a prior PD-1 pathway-targeted agent.
* Subjects with melanoma:

  * Histologically or cytologically confirmed melanoma.
  * Unresectable Stage III or Stage IV melanoma, as per American Joint Committee on Cancer staging system not amenable to local therapy.
* Subjects with urothelial carcinoma:

  * Histologically or cytologically confirmed urothelial carcinoma of the renal pelvis, ureter, urinary bladder, or urethra that is transitional cell or mixed transitional/nontransitional (predominantly transitional) cell type.
  * Stage IV locally advanced or metastatic urothelial carcinoma (according to American Joint Committee on Cancer 7th edition guidelines) with documented disease progression while on a PD-1 pathway targeted therapy.

Exclusion Criteria:

* Laboratory parameters not within the protocol-defined range.
* Receipt of anticancer medications or investigational drugs within a defined interval before the first administration of study drug.
* Has not recovered from toxic effects of prior therapy to ≤ Grade 1.
* Active or inactive autoimmune disease or syndrome.
* Active infection requiring systemic therapy.
* Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
* History or presence of an abnormal ECG that, in the investigator's opinion, is clinically meaningful.
* Has received a live vaccine within 30 days of planned start of study therapy.
* Prior receipt of an IDO inhibitor.
* Subjects with uncontrolled type I or type II diabetes mellitus (defined as HgbA1c \> 8).
* Prior receipt of a BET inhibitor (Treatment Group B only).
* Subjects with a history of bleeding related to cancer under study requiring a medical intervention (eg, embolization procedure, RBC transfusion, or hospitalization) within 30 days of study enrollment (Treatment Groups B and C only).
* Clinically significant bleeding within 14 days of Cycle 1 Day 1 (Treatment Groups B and C only).
* Prior receipt of an LSD1 inhibitor including INCB059872 (Treatment Group C only).

Primary outcomes:
measure: Part 1 and 2 : Number of Participants With Treatment Emergent Adverse Events
timeFrame: Baseline through 42-49 days after end of treatment, estimated up to 27 months (24 months with 100 day FU period).
measure: Part 1 and 2: Objective Response Rate Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
timeFrame: Every 9 weeks for the duration of study participation; estimated minimum of 6 months.
Secondary outcomes:
measure: Parts 1 and 2: Percentage of Responders Determined by Immunohistochemistry
timeFrame: Baseline to Week 5/6 or week 8/9
measure: Parts 1 and 2: Progression-free Survival Based on RECIST v1.1.
timeFrame: Every 9 weeks from date of randomization until the date of first documented progression or date of death from any cause whichever came first, assessed up to 24 months
measure: Parts 1 and 2: Duration of Response Based on RECIST v1.1
timeFrame: Every 9 weeks from date of randomization until the date of first documented progression or date of death from any cause whichever came first, assessed up to 24 months
Other outcomes:
Locations:
city: Duarte
country: United States
facility: City of Hope National Medical Center
state: California
city: La Jolla
country: United States
facility: University of California San Diego
state: California
city: Chicago
country: United States
facility: The University of Chicago
state: Illinois
city: Philadelphia
country: United States
facility: University of Pennsylvania Health System
state: Pennsylvania
city: Nashville
country: United States
facility: Sarah Cannon
state: Tennessee
city: Nashville
country: United States
facility: Vanderbilt-Ingram Cancer Center
state: Tennessee
city: Houston
country: United States
facility: MD Anderson Cancer Center
state: Texas
city: Seattle
country: United States
facility: University of Washington
state: Washington
city: Barcelona
country: Spain
facility: Vall D Hebron Univ
city: Pamplona
country: Spain
facility: Univ De Navarra
city: London
country: United Kingdom
facility: University College London Hospitals (Uclh)
city: Oxford
country: United Kingdom
facility: Churchill Hospital
Study officials:
affiliation: Incyte Corporation
name: Kevin O'Hayer, MD
role: STUDY_DIRECTOR
References: